Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://covid19.nih.gov/

Principal Investigator
Name
Lauren Connell
Institution
Independent
Position Title
Student at Naples High School
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-691
Initial CDAS Request Approval
Nov 17, 2020
Title
An examination of the relationship between specific driver mutations, target drugs, and immunotherapies in non-small cell lung cancer survival outcomes.
Summary
In the project I am completing, I am looking at the relationship cancer has with known biomarkers, treatments, and drugs in order to identify positive survival factors to add to what is know about cancer treatments. Lung Cancer is the number one killer in the United States, with the National Cancer Institute estimating 228,820 new cases will be diagnosed in 2020. The five-year survival rate is estimated to be 20.5%. Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC; Adenocarcinoma, Squamous cell carcinoma and other) overall survival rates have been researched and specific genetic mutations have been identified as holding potentially effective treatment options. Research on biomarkers, driver mutations, mutation specific antibodies has propelled increasing interest in creating treatments to improve overall survival in NSCLC. In particular, the use of genetically specific mutations/variations and targeted treatments lends hope to increased survival rates. Precision in diagnoses and treatments can be life changing. I seek to examine, with statistics, this area of NCSLC treatment efficacy.
Aims

1. To determine the relationship of specific driver mutations in NSCLC (KRAS, EGFR), targeted drug treatments and immunotherapies on overall survival.
2. To determine the efficacy of immunotherapies as a first line approach to NSCLC treatment (with and without angiogenesis inhibitors).
3. To analyze the PLCO dataset using commonly available patient data (i.e., age, ethnicity, years smoking, stage, etc.,) from the PLCO.
4. To perform an analysis to find out the values of biomarkers, therapies that maximize the overall survival benefits.
5. To help integrate target drug annotation of variants in NSCLC.

Collaborators

Lauren Connell, Naples High School